# Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

> **NCT03656510** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 246 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** JNJ-53718678
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03656510
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-29
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 246 (ACTUAL)
- **Why stopped:** Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656510, "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03656510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*